Quantcast
Home > Quotes > PTLA
PTLA

Portola Pharmaceuticals, Inc. Common Stock (PTLA) Quote & Summary Data

$35.4
*  
0.95
2.76%
Get PTLA Alerts
*Delayed - data as of Apr. 23, 2019  -  Find a broker to begin trading PTLA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    PTLA Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
43.5
Today's High / Low
$ 35.62 / $ 34.20
Share Volume
817,821
50 Day Avg. Daily Volume
1,161,886
Previous Close
$ 34.45
52 Week High / Low
$ 45.60 / $ 14.81
Market Cap
2,407,840,669
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -5.30
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
2.04

Intraday Chart

Shares Traded

Share Volume:
817,821
50 Day Avg. Daily Volume:
1,161,886

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -5.30

Trading Range

The current last sale of $35.40 is 139.03% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 35.62 $ 45.60
 Low: $ 34.20 $ 14.81

ETFs with PTLA as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
1.72% SPDR Series Trust SPDR S&P Biotech ETF (XBI) +7.03 (8.80%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

Portola Pharmaceuticals, Inc.® (the "Company" or "we" or "our" or "us") is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic diseases and inflammation for patients who currently have limited or no approved treatment options. Our headquarters are located in South San Francisco, California. Our lead product is Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote approved by the U.S. Food and Drug Administration ("FDA") for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.  ... More ...  



Risk Grade

Where does PTLA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 34.50
Open Date:
Apr. 23, 2019
Close Price:
$ 35.40
Close Date:
Apr. 23, 2019


Consensus Recommendation

Analyst Info